Sofosbuvir and Daclatasvir for Treating Hepatitis C in 200 Patients Co-infected With Human Immunodeficiency Virus
Status:
Completed
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
In a multi-center study 200 patients co-infected with hepatitis C virus (HCV) and human
immunodeficiency virus (HIV) will be treated with a fixed-dose combination pill combined of
400 mg sofosbuvir and 30, 60, or 90 mg of daclatasvir - depending on the particular
antiretroviral treatment (ART) being used by the patient. The treatment duration will be 12
weeks for subjects without cirrhosis and 24 weeks for those with cirrhosis.